Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above Fifty Day Moving Average - Here's Why

Key Points

• Theravance Biopharma's stock price recently surpassed its 50-day moving average of $13.79, reaching a high of $14.16 during trading.
• Analysts have mixed ratings for Theravance Biopharma, with a consensus target price of $23.00 and a consensus rating of "Buy."
• Institutional investors significantly increased their stake in the company, with 99.10% of the stock owned by hedge funds and other institutional investors.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $13.79 and traded as high as $14.16. Theravance Biopharma shares last traded at $14.04, with a volume of 314,447 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. B. Riley assumed coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They set a "buy" rating and a $28.00 target price on the stock. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Theravance Biopharma in a research report on Wednesday, October 8th. Zacks Research lowered shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 15th. BTIG Research raised their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, June 27th. Finally, Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $23.00.

Theravance Biopharma Price Performance

The company has a market capitalization of $707.05 million, a PE ratio of 58.50 and a beta of -0.03. The company's fifty day moving average is $13.79 and its 200-day moving average is $11.40.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. grew its holdings in Theravance Biopharma by 1,629.4% in the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company's stock worth $6,055,000 after purchasing an additional 390,735 shares during the last quarter. Nuveen LLC purchased a new position in Theravance Biopharma in the first quarter worth $3,348,000. Jefferies Financial Group Inc. grew its holdings in Theravance Biopharma by 1,191.9% in the second quarter. Jefferies Financial Group Inc. now owns 276,887 shares of the biopharmaceutical company's stock worth $3,054,000 after purchasing an additional 255,455 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Theravance Biopharma by 121,993.7% in the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after purchasing an additional 174,451 shares during the last quarter. Finally, Qube Research & Technologies Ltd grew its holdings in Theravance Biopharma by 80.2% in the second quarter. Qube Research & Technologies Ltd now owns 205,280 shares of the biopharmaceutical company's stock worth $2,264,000 after purchasing an additional 91,341 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.